Sentiment Summary
Recent Events
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
Q4 FY2026 earnings release scheduled for 2026-07-29. Estimated 1% price impact for the announcement.
Q2 2026 earnings release is scheduled. This is estimated to have a low impact (~1%) as a routine announcement, scheduled.
Ex-dividend date for the final 2025 dividend of US$0.041446 per share on June 30, 2026, announced on March 26, 2026; Low importance is estimated due to typical minor price adjustments, scheduled.
Quarterly dividend of $0.26 per share, ex-dividend date on 2026-06-17. The dividend was announced on May 21, 2026. Estimated 1% price impact as a routine corporate action.
KLA Corp. will execute a ten-for-one forward stock split on June 12, 2026, with trading beginning on a split-adjusted basis scheduled. High importance is estimated due to the significant impact of stock splits on liquidity and retail accessibility.
Apple's annual Worldwide Developers Conference (WWDC) keynote featuring AI strategy and iOS 27 is scheduled. Medium importance is estimated due to high market expectations for AI announcements likely causing a >5% price impact scheduled.
Ex-dividend date on June 4, 2026, for the increased quarterly cash dividend of $0.25 per share, scheduled to be paid on June 26, 2026.
Final dividend for fiscal year 2025 of RMB 0.14 per share (approx. HKD 0.158-0.161 per share) goes ex-dividend on 2026-06-01. The dividend was approved at the AGM on 2026-05-28 and is payable on 2026-07-23.
Announced that CVS Caremark will restore preferred formulary coverage for its weight-loss drug Zepbound effective October 1, 2026, and add its oral drug Foundayo effective June 1, 2026, significantly expanding patient access. High importance is estimated due to the expected >10% price impact from increased market reach.
Announced that its Class 1 innovative drug, Luzhunolei Sodium Tablets (SHR4640), was approved for marketing by the National Medical Products Administration of China. This is the first domestically developed high-selectivity URAT1 inhibitor for treating hyperuricemia in gout patients. This approval is expected to have a >=5% price impact due to the drug's market potential. expected
The 2025 Annual General Meeting was held on 2026-05-28, where all proposed resolutions were passed. Subsequently, the 11th session of the Board of Directors was formed, re-electing Mr. Liu Lei as Chairman.
Geely launched its new 'Xingyuan' (Star Wish) model, an electric vehicle with variants offering 410km and 480km range, with promotional prices starting from 61,800 RMB. Analysts estimate this new model launch will result in a 1-5% price impact, expected.
JD Logistics repurchased 2.439 million shares for approximately HK$31.54 million on May 28, 2026. Low importance as the buyback size is small relative to market capitalization, likely causing >=1% price impact.
UBS raised its target price for SITC from HK$30 to HK$33.8, maintaining a "Neutral" rating. The revision reflects stronger-than-expected freight rates and volumes for Q2 2026, with management expecting year-over-year growth forecasted.
JD Logistics opened the Lingshui Intelligent Logistics Hub in Hainan on May 27, 2026. Low importance as this operational milestone is expected to have a minor immediate market impact of >=1%.
Mastercard was granted a BitLicense by the New York State Department of Financial Services on 2026-05-27; low importance is estimated due to the <5% price impact expected.
Announced agreements on 2026-05-26 to acquire three vaccine development companies (Curevo, LimmaTech Biologics, Vaccine Company) for up to $3.83 billion to expand its pipeline into infectious diseases. High importance is estimated as this major acquisition is expected to have a >10% price impact.
Morgan Stanley lowered its price target for Mao Geping to HK$72 on 2026-05-26, citing lower profit margin expectations and increased advertising spending, as analysts reduced 2026 and 2027 earnings per share estimates by 5% and 7% respectively, which is expected to lead to a stock price drop, forecasted.
On 2026-05-25, Seres announced progress on a capital increase for its subsidiary Chongqing Landian Technology. Following the RMB 6.67 billion investment from external parties including a CATL subsidiary, Seres will no longer hold a controlling stake, effectively spinning off the lower-end Landian brand to focus on the premium AITO brand. Analysts estimate this strategic shift will have a ~5% impact on valuation.